SOURCE: The Bedford Report

The Bedford Report

November 09, 2010 08:46 ET

Obama Extends an Olive Branch to the Biotech Industry

The Bedford Report Provides Analyst Research on Gilead Sciences & Biogen Idec

NEW YORK, NY--(Marketwire - November 9, 2010) -  Biotech companies have not been impervious to the economic downturn but they have endured better than most. This is partly due to the fact that demand for pharmaceuticals remains fairly constant even during recession. At the moment there is plenty of optimism regarding the Biotech Industry as firmer pricing and new products have improved sales and earnings trends this year. While healthcare reform is likely to shake up this industry, a recent gesture of goodwill from the Obama administration has curtailed some concern. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Gilead Sciences, Inc. (NASDAQ: GILD) and Biogen Idec Inc. (NASDAQ: BIIB). Access to the full company reports can be found at:

Recently the Obama administration pressed congress to revamp a research and development tax credit by increasing it by about 20 percent and make it permanent. The Pharmaceutical Research and Manufacturers of America, PhRMA, as well as the Advanced Medical Technology Association expressed support for the tax credit.

The Bedford Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us for free at and get exclusive access to our numerous analyst reports and industry newsletters.

The new healthcare reform bill could lead to significance ramifications for biotech companies. Over the next decade, the biotech industry is expected to lose $105 billion as result of the healthcare bill. Analyst consensus is that this will be partially offset by the additional 32 million Americans insured as a result on the bill.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information